DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Ultrasound Homepage

GE to provide training to at least 140 Kenyan radiographers Partnering with Society of Radiography in Kenya

GE launches Invenia ABUS 2.0 in US Fifty five percent more efficient in detecting breast cancer than mammography alone

Virginia med school to offer portable ultrasound with 12-lead ECG technology Viewing the heart and measuring electrical activity

Facebook 'viable' medium for critical care ultrasound training, say studies Positive response from 90 percent of participants

Clarius Mobile Health unveils wireless Clarius Cart Traditional cart-based system without cables

Avante acquires Ultra Solutions Expands inventory and service and repair capabilities

Sacramento Ultrasound Institute deploys SonicDICOM PACS system Accessible through the school's student portal

Butterfly iQ begins taking orders on iPhone compatible ultrasound First ultrasound-on-a-chip-based imaging system has price tag under $2,000

AI drives first ejection fraction cardiac software tool for mobile ultrasound DiA Imaging Analysis platform now available with GE's Vscan handheld ultrasound

Could a Band-Aid-sized $100 ultrasound transducer be coming soon? Researchers are optimistic, as image quality matches or exceeds conventional systems

The FDA has cleared a phase 2a trial
for using focused-ultrasound in
enhancing the delivery of drugs
to the brain for Alzheimer's
treatment

FDA greenlights focused ultrasound trial for Alzheimer's treatment

John R. Fischer , Staff Reporter
The FDA has cleared the way for researchers to initiate a clinical study that will utilize MR-guided focused ultrasound to noninvasively open the blood-brain barrier (BBB) for enhancing the treatment of Alzheimer’s disease.

The multicenter, single-arm phase 2a trial follows a smaller one conducted by researchers in Toronto to evaluate the efficiency and safety of INSIGHTEC’s Exablate Neuro low-frequency ultrasound for temporarily opening the BBB of five AD patients repeatedly, to enable better delivery of drugs for Alzheimer’s and other neurodegenerative diseases. The phase 2a trial will evaluate the approach in a larger set of patients.

Story Continues Below Advertisement

Dunlee announces the relaunch of DA135 CT/e, DA165NP and Akron tubes

Dunlee announces the return of the DA135 CT/e, DA165NP, S532B and S532Q(known as the Akron tubes) CT Replacement tubes, making its full portfolio of CT tubes for GE and Siemens CT scanners available once again.Click to learn more



“The most common way through the blood-brain barrier is to inject hypertonic mannitol in the arteries going to the brain,” Dr. Neal Kassell, chairman of the Focused Ultrasound Foundation, told HCB News. “It opens the blood-brain barrier in the territory in which the arteries are feeding the brain. It’s sort of an indiscriminate approach and invasive and incredibly awkward to do. Focused ultrasound can be done in a very highly targeted manner and can be done to open the blood-brain barrier temporarily and reversibly; and it can be done repetitively.”

More than 6.4 million people in North America and 44 million worldwide are afflicted by dementia, with Alzheimer’s being the most common form.
While efficient at protecting the brain from toxins and infectious agents, the BBB blocks the entry of drugs treating diseases such as AD, with many unable to breach it due to their large sizes.

Utilizing low frequency ultrasound waves, Canadian researchers at Sunnybrook Health Sciences Centre in the phase one trial were able to noninvasively open the BBB in a small area of the frontal lobe in patients between 50 and 85 in the beginning stages of AD. They previously applied this approach in 2015 to evaluate the delivery of chemotherapy to brain tumors.

The trial was conducted to evaluate safety and feasibility in the repeated opening of the BBB with focused ultrasound, taking part in two stages. The first involved opening a small area of the brain to temporarily open the BBB, followed approximately one month later by the second, which involved opening a larger area. No drugs were administered in this study.

Published in Nature Communications, the trial is the first clinical, peer-reviewed report to evaluate feasibility and safety in opening the BBB in AD patients. The findings were presented last month at the Alzheimer’s Association International Conference (AAIC) in Chicago.

“Opening the blood-brain barrier in a so-called temporary and safe way is really important not just for Alzheimer’s disease but for administering drugs for treating Parkinson’s disease, brain tumors and other serious conditions,” said Kassell. “It’s a very exciting area, this focused ultrasound opening up the blood-brain barrier.”

The phase one trial, he adds, is just the “first small step” with the next being the phase 2a trial, and eventually another involving the administration of drugs into the brain.

The phase 2a trial is expected to begin this fall.

Ultrasound Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2018 DOTmed.com, Inc.
版权所有